Teledyne Technologies has settled into a quieter groove after the post-earnings surge, but the most striking development this week isn't the price — it's how aggressively short sellers have unwound since July 22.
The short-covering story has accelerated sharply. Short interest has fallen 27% in a single week to 2.2% of the free float — down from around 3.0% noted in the previous note, and off more than 31% over the past month. That represents roughly half a million shares covered in less than five sessions. At current levels, short interest is approaching the low end of what might be considered a structural baseline for a name of this size. The borrow market confirms there is no friction: availability has expanded to 2,697% — meaning shares available to borrow now exceed the entire short position by nearly twenty-seven times — and cost to borrow holds near 0.43%, near its lowest reading in months. Nothing in the lending market suggests any residual conviction on the short side.
Options positioning has shifted modestly but remains worth watching. The put/call ratio ticked up to 1.07 this week, running a little above its 20-day average of 0.93, though the z-score of 0.62 keeps it well within normal range. The more notable move is the structural shift: the PCR was in the 0.70–0.72 range through most of June and early July, spiked sharply around the July 13 reading to 1.56 — the 52-week high — and has now settled into a new, modestly higher range around 1.06–1.07 for four consecutive sessions. That pattern suggests the post-earnings hedges haven't fully been removed, even as short positions have. Investors appear to be running lighter protection than pre-earnings but more than they were in June.
The Street responded to the Q2 beat with a cluster of target upgrades. Stifel lifted its Buy-rated target to $775 from $750, and Needham raised its Buy target to $750 from $735, both on July 23. Barclays was less enthusiastic — raising its Equal-Weight target to $640, still below the current price of $649.67, effectively signalling the sidelines. Consensus sits at a Buy with a mean target of $753.50, implying about 16% upside from here. Bulls point to TDY's defense growth, the Q2 beat, and acquisition optionality. Bears flag short-cycle industrial softness, government spending uncertainty, and a valuation that, at roughly 25x trailing earnings and 19x EV/EBITDA, leaves limited room for execution stumbles. The ORTEX short score has eased to 33.8, its lowest in the observed history and down from 38.5 two weeks ago, consistent with the directional shift in positioning.
Among the closest correlated peers, the week told a mixed story. VNT gained 8.6% on the week while BDC added 2.8%, suggesting some pockets of industrial-tech strength. AEIS fell nearly 10% and KEYS dropped 7%, pointing to selective earnings-driven dispersion rather than a uniform sector move. INVZ was the outlier, down 32% on the week, but the correlation is too low to read much into it for TDY specifically. Against that backdrop, TDY's flat-to-slightly-up week looks relatively resilient.
T. Rowe Price added 608,622 shares in the quarter to June 30 — the largest institutional add in the top-holder list — bringing its stake to 7.8% of shares, second only to BlackRock. JP Morgan Asset Management added 263,000 shares over the same period. The institutional flow narrative broadly supports the stock, even if the pace of near-term covering by shorts has now run well ahead of what fresh institutional buying alone would explain.
With no next earnings event yet scheduled and the post-print short covering largely complete, the next data point to watch is whether the elevated put/call ratio — now holding in the 1.06–1.07 range for four sessions — continues to normalise or builds again on any sign of industrial macro weakness in the coming weeks.
See the live data behind this article on ORTEX.
Open TDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
